

Optimization of Mammalian Cell Culture Media for In Vitro Photosynthetic Co-Culture with Cyanobacteria *Synechococcus elongatus*



Athena J. Chien^{1,2}, Hanjay Wang¹, Matthew A. Wu¹, Camille E. Hironaka¹, Justin M. Farry¹, Kiah M. Williams¹,

Michael J. Paulsen¹, Lyndsay M. Stapleton^{1,3}, Amanda N. Steele^{1,3}, Y. Joseph Woo^{1,3}

¹Department of Cardiothoracic Surgery Stanford University, Palo Alto, CA, ²Department of Bioengineering Rice University, Houston, TX,

³Department of Bioengineering Stanford University, Palo Alto, CA

Motivations


- S. elongatus* is capable of generating O₂ in the presence of light, via photosynthesis
- When injected into infarcted ventricle in rats *in vivo*, *S. elongatus* enhances oxygenation and cardiac output leading to improved cardiac function after heart attack¹
- S. elongatus* has no significant immune response in rats²

Current Limitations


- S. elongatus* cultured in specialized BG11 media
- Cardiomyocytes and other mammalian cells are typically cultured in Dulbecco's Modified Eagle Medium (DMEM)
- A suitable co-culture media is needed to study the symbiotic relationship *in vitro*
- Hypothesis:** Mammalian cell culture media (DMEM) can be altered to improve *S. elongatus* viability, thereby enabling study & optimization of the biologic mechanisms to develop the symbiotic therapy

Culturing *S. elongatus*

- Cultured in glass 25 mL Erlenmeyer flasks in a rotating incubator under fluorescent lighting 34 °C and 125 rpm
- Purity checks were performed either by ensuring no growth when the liquid cultures were plated on Luria broth agar, or by ensuring no heterogeneous bacterial subpopulations by microscopy
- Grow to early stationary phase in BG11 cyanobacteria culture media, then aliquot 10 mL and resuspend in the desired media
- S. elongatus* monitored for 7 days via spectrophotometry (min. n=6)




(A) *S. elongatus* auto fluorescent,
no contaminant present




(B) 10 mL control
flask,
covered with
aluminum foil cap

Preliminary Experimentation



Modifying Mammalian Cell Media for *S. elongatus*




* DMEM is significantly different from BG11 (ANOVA and Tukey's HSD, p< 0.05)
DMEM without antibiotics is significantly different from BG11

Figure 1. *S. elongatus* in DMEM without Penicillin/Streptomycin compared to positive and negative controls (BG11, DMEM)

***S. elongatus* grew significantly better after 7 days in DMEM without antibiotics compared to BG11 and DMEM with all additives.**

Removing Phenol Red for Optical Observation



DMEM w/o P/S, Phenol Red is significantly different from BG11 (ANOVA and Tukey's HSD, p< 0.05)

* DMEM statistically different from BG11 control (p<0.05)

% DMEM w/o Phenol Red statistically different from BG11 control (p<0.05)

Figure 2. Removing phenol red to enable visual estimation of *S. elongatus* viability visually (green).

***S. elongatus* grew significantly better after 7 days in DMEM without phenol red and antibiotics compared to BG11, DMEM without Phenol Red, and DMEM with all additives.**

Conclusions

- S. elongatus* is capable of maintaining in early stationary phase for 7 days in **DMEM without pen/strep, & DMEM without pen/strep, phenol red**
- This result enables the possibility of studying a co-culture of *S. elongatus* with mammalian cells *in vitro* over 7 days – for development of a symbiotic therapy leveraging the photosynthetic capabilities of cyanobacteria

Future Directions

- Measuring **oxygen production** of *S. elongatus* in DMEM w/o pen/strep, w/o phenol red to ensure cyanobacteria maintains therapeutic oxygen production in the new media
- Viability assessment of **co-culturing** cyanobacteria and neonatal rat cardiomyocytes

References & Acknowledgements

- Cohen, J. E., A. B. Goldstone, M. J. Paulsen, et al. An innovative biological system for photon-powered myocardium in the ischemic heart. *Science Advances*, 3(6), 2017.
- Williams, K. M., H. Wang, M. J. Paulsen, A. D. Thakore, et al. Safety of photosynthetic *synechococcus elongatus* for *in vivo* cyanobacteria-mammalian symbiotic therapeutics. *Microb. Biotechnol.* 0(0), 1-13, 2020.

This work was funded in part by the National Institutes of Health (5R01HL089315-11 to Y.J.W.) and the American Heart Association (18POST33990223 to H.W., 17POST33410497 to M.J.P.).